Abstract
The efficacy and tolerability of osmotic-release oral system (OROS) methylphenidate in adolescents with attention deficit hyperactivity disorder (ADHD) were evaluated in a multisite controlled study at the Massachusetts General Hospital, Boston, and other centers in the United States.
Highlights
The efficacy and tolerability of osmotic-release oral system (OROS) methylphenidate in adolescents with attention deficit hyperactivity disorder (ADHD) were evaluated in a multisite controlled study at the Massachusetts General Hospital, Boston, and other centers in the United States
Investigator, parent and patient report measures showed a significant reduction from baseline in ADHD symptoms in 52% of subjects treated with OROS compared to 31% of those receiving placebo
OROS methylphenidate is effective in 50% of adolescents with ADHD following a short-term trial, but larger doses than usual are required in more than one-third of patients
Summary
The efficacy and tolerability of osmotic-release oral system (OROS) methylphenidate in adolescents with attention deficit hyperactivity disorder (ADHD) were evaluated in a multisite controlled study at the Massachusetts General Hospital, Boston, and other centers in the United States. Of 220 adolescents who entered the study, 177 completed an initial dose titration phase and were randomized to receive 2 weeks' treatment with their individualized, effective and tolerated dosage (18, 36, 54, or 72 mg once daily) or placebo. Investigator, parent and patient report measures showed a significant reduction from baseline in ADHD symptoms in 52% of subjects treated with OROS compared to 31% of those receiving placebo.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
